MA31260B1 - 3-imidazolyl-indoles pour le traitement de maladies proliferatives - Google Patents
3-imidazolyl-indoles pour le traitement de maladies proliferativesInfo
- Publication number
- MA31260B1 MA31260B1 MA32230A MA32230A MA31260B1 MA 31260 B1 MA31260 B1 MA 31260B1 MA 32230 A MA32230 A MA 32230A MA 32230 A MA32230 A MA 32230A MA 31260 B1 MA31260 B1 MA 31260B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- proliferative diseases
- indoles
- imidazolyl
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention porte sur des composés 3-hétérocyclyl indolylés, capables d'inhiber l'interaction entre p53, ou des variantes de celui-ci, et mdm2 et/ou mdm4, ou des variantes de ceux-ci, respectivement, lesdits composés ayant la formule (i) dans laquelle r1, r2, r3, r4, ra, y et y sont tels que définis dans la description. En raison de leur activité, les composés sont utiles dans le traitement de divers troubles et diverses maladies à médiation par l'activité de mdm2 et/ou mdm4, ou des variantes de ceux-ci, tels que des maladies inflammatoires ou prolifératives ou dans la protection de cellules.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07105269 | 2007-03-29 | ||
PCT/EP2008/053667 WO2008119741A2 (fr) | 2007-03-29 | 2008-03-27 | 3-imidazolyl-indoles pour le traitement de maladies prolifératives |
Publications (1)
Publication Number | Publication Date |
---|---|
MA31260B1 true MA31260B1 (fr) | 2010-03-01 |
Family
ID=38328915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA32230A MA31260B1 (fr) | 2007-03-29 | 2009-09-24 | 3-imidazolyl-indoles pour le traitement de maladies proliferatives |
Country Status (27)
Country | Link |
---|---|
US (1) | US8053457B2 (fr) |
EP (1) | EP2142535A2 (fr) |
JP (1) | JP2010522723A (fr) |
KR (1) | KR20090122403A (fr) |
CN (1) | CN101679382A (fr) |
AR (1) | AR065860A1 (fr) |
AU (1) | AU2008234954B9 (fr) |
BR (1) | BRPI0810082A2 (fr) |
CA (1) | CA2682483A1 (fr) |
CL (1) | CL2008000899A1 (fr) |
CR (1) | CR11019A (fr) |
DO (1) | DOP2009000229A (fr) |
EA (1) | EA200901212A1 (fr) |
EC (1) | ECSP099660A (fr) |
GT (1) | GT200900256A (fr) |
IL (1) | IL200862A0 (fr) |
MA (1) | MA31260B1 (fr) |
MX (1) | MX2009010413A (fr) |
NI (1) | NI200900177A (fr) |
PA (1) | PA8774001A1 (fr) |
PE (1) | PE20081897A1 (fr) |
SM (1) | SMP200900085B (fr) |
TN (1) | TN2009000388A1 (fr) |
TW (1) | TW200843746A (fr) |
UY (1) | UY30987A1 (fr) |
WO (1) | WO2008119741A2 (fr) |
ZA (1) | ZA200906210B (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007117401A2 (fr) * | 2006-04-07 | 2007-10-18 | Janssen Pharmaceutica N.V. | Indoles et benzoimidazoles modulateurs du récepteur de l'histamine h4 |
AR070398A1 (es) * | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
US20100035862A1 (en) * | 2008-06-25 | 2010-02-11 | Abbott Laboratories | Novel aza-cyclic indole-2-carboxamides and methods of use thereof |
MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
BRPI1007334A2 (pt) * | 2009-01-16 | 2016-02-10 | Daiichi Sankyo Co Ltd | composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. |
JP2012102017A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | インドール化合物 |
WO2010119984A1 (fr) * | 2009-04-16 | 2010-10-21 | Banyu Pharmaceutical Co.,Ltd. | Dérivé d'indole substitué en position 3 par aryle ou hétéroaryle |
WO2011060049A2 (fr) | 2009-11-12 | 2011-05-19 | The Regents Of The University Of Michigan | Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 |
WO2011106650A2 (fr) * | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Nouveaux antagonistes de p53-mdm2/p53-mdm4 pour traiter une maladie de prolifération |
JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
EP2614051A4 (fr) * | 2010-09-08 | 2014-01-29 | Univ Pittsburgh | Antagonistes de p53-mdm2 |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
UA109464C2 (uk) | 2010-11-12 | 2015-08-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи mdm2 |
US20120202794A1 (en) * | 2011-01-24 | 2012-08-09 | Pharmasset, Inc. | Compounds |
EP2684880B1 (fr) | 2011-03-10 | 2018-02-28 | Daiichi Sankyo Company, Limited | Dérivé de dispiropyrrolidine |
CN102702066A (zh) * | 2011-03-28 | 2012-10-03 | 苏州百灵威超精细材料有限公司 | 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法 |
PL2691443T3 (pl) | 2011-03-28 | 2021-08-30 | Massachusetts Institute Of Technology | Sprzężone lipomery i ich zastosowania |
CA2835422C (fr) | 2011-05-11 | 2016-10-11 | The Regents Of The University Of Michigan | Agonistes de mdm2 consistant en spiro-oxindoles |
WO2012177927A1 (fr) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Animaux transgéniques pouvant être induits pour éliminer des cellules sénescentes |
WO2012176123A1 (fr) * | 2011-06-22 | 2012-12-27 | Novartis Ag | 3-imidazolyl-indoles pour traiter les maladies prolifératives |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
CA2859385A1 (fr) | 2011-12-13 | 2013-06-20 | Buck Institute For Research On Aging | Procedes d'amelioration de therapies medicales |
WO2013158664A2 (fr) | 2012-04-17 | 2013-10-24 | Kythera Biopharmaceuticals, Inc. | Utilisation de virus modifiés pour tuer spécifiquement les cellules sénescentes |
EP2882706A1 (fr) | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Lipidoïdes contenant des amines et leurs utilisations |
US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
CA2895504A1 (fr) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Imidazopyridines substituees en tant qu'inhibiteurs de hdm2 |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
WO2015116735A1 (fr) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Procédés et combinaisons pour tuer des cellules sénescentes et traiter des maladies et troubles associés à une sénescence |
SG10201805670QA (en) | 2014-01-28 | 2018-08-30 | Buck Inst Res Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
EP3139942B1 (fr) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | Compositions et procédés d'inhibition de protéines antiapoptotiques bcl-2 comme agents anti-âge |
US9840479B2 (en) | 2014-07-02 | 2017-12-12 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
WO2016001376A1 (fr) | 2014-07-03 | 2016-01-07 | Boehringer Ingelheim International Gmbh | Nouveaux composés et dérivés spiro [3h-indole-3,2'-pyrrolidine]-2(1h)-one en tant qu'inhibiteurs de mdm2-p53 |
WO2016014625A1 (fr) | 2014-07-22 | 2016-01-28 | Board Of Trustees Of The University Of Arkansas | Compositions et procédés de déplétion sélective de cellules sénescentes |
JP2018502846A (ja) | 2014-12-26 | 2018-02-01 | ダウ グローバル テクノロジーズ エルエルシー | 有機化合物、及び有機化合物を含む有機層を備える電子デバイス |
TWI711452B (zh) | 2015-02-20 | 2020-12-01 | 日商第一三共股份有限公司 | 癌症的倂用治療法 |
TWI697329B (zh) | 2015-04-13 | 2020-07-01 | 日商第一三共股份有限公司 | 血液癌症治療用之醫藥及其用途 |
CA2990076A1 (fr) * | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Conjugues anticorps-medicament (adc) et conjugues lieur-promedicament (apdc) a groupes enzymatiquement clivables |
JOP20160198B1 (ar) * | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
WO2017060431A1 (fr) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Composés de spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one et leurs dérivés à titre d'inhibiteurs de mdm2-p53 |
CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
EP3440082A1 (fr) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Intermédiaires monofonctionnels pour la dégradation d'une protéine cible dépendante du ligand |
CA3018991A1 (fr) | 2016-04-21 | 2017-10-26 | Bioventures, Llc | Composes induisant la degradation de proteines anti-apoptotiques de la famille bcl-2 et utilisation de ces derniers |
CN105906610B (zh) * | 2016-05-24 | 2018-10-23 | 绍兴文理学院 | 一种3-(4-苯基-1h-咪唑-5-基)-1h-吲哚衍生物及其制备方法和应用 |
HUE045355T2 (hu) * | 2016-07-21 | 2019-12-30 | Inst Farmakologii Polskiej Akademii Nauk | Az 5-HT7 szerotoninreceptort kötõ imidazolil-szubsztituált indolszármazékok és gyógyszerészeti készítményeik |
WO2018074387A1 (fr) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Procédé de polythérapie utilisant un inhibiteur de mdm2 et un inhibiteur d'adn méthyltransférase |
WO2018096159A1 (fr) * | 2016-11-28 | 2018-05-31 | F. Hoffmann-La Roche Ag | Oxadiazolones en tant qu'inhibiteurs de canal potentiel récepteur transitoire |
IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
JP7178357B2 (ja) | 2017-03-07 | 2022-11-25 | エフ.ホフマン-ラ ロシュ アーゲー | オキサジアゾール一過性受容器電位チャネル阻害剤 |
WO2018185135A1 (fr) | 2017-04-05 | 2018-10-11 | Boehringer Ingelheim International Gmbh | Polythérapie anticancéreuse |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
CN111163774A (zh) * | 2017-05-26 | 2020-05-15 | 罗格斯新泽西州立大学 | 细菌外排泵抑制剂 |
US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣3多肽之持續遞送 |
TW202241873A (zh) * | 2020-12-22 | 2022-11-01 | 瑞士商諾華公司 | 用於治療與cgas相關的病症之化合物及組成物 |
WO2022204235A1 (fr) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Composés bicycliques en tant que modulateurs du récepteur des androgènes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19948417A1 (de) * | 1999-10-07 | 2001-04-19 | Morphochem Ag | Imidazol-Derivate und ihre Verwendung als Arzneimittel |
JP2002114780A (ja) * | 2000-10-11 | 2002-04-16 | Taisho Pharmaceut Co Ltd | 4−(3−インドリル)イミダゾール誘導体 |
CN102627649B (zh) | 2005-02-22 | 2015-03-25 | 密执安州立大学董事会 | Mdm2的小分子抑制剂以及其应用 |
US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
-
2008
- 2008-03-27 PE PE2008000554A patent/PE20081897A1/es not_active Application Discontinuation
- 2008-03-27 BR BRPI0810082-9A2A patent/BRPI0810082A2/pt not_active IP Right Cessation
- 2008-03-27 US US12/593,721 patent/US8053457B2/en not_active Expired - Fee Related
- 2008-03-27 EP EP08735532A patent/EP2142535A2/fr not_active Withdrawn
- 2008-03-27 CA CA002682483A patent/CA2682483A1/fr not_active Abandoned
- 2008-03-27 AR ARP080101262A patent/AR065860A1/es unknown
- 2008-03-27 MX MX2009010413A patent/MX2009010413A/es not_active Application Discontinuation
- 2008-03-27 CN CN200880017611A patent/CN101679382A/zh active Pending
- 2008-03-27 JP JP2010500280A patent/JP2010522723A/ja active Pending
- 2008-03-27 EA EA200901212A patent/EA200901212A1/ru unknown
- 2008-03-27 KR KR1020097022526A patent/KR20090122403A/ko not_active Application Discontinuation
- 2008-03-27 WO PCT/EP2008/053667 patent/WO2008119741A2/fr active Application Filing
- 2008-03-27 AU AU2008234954A patent/AU2008234954B9/en not_active Ceased
- 2008-03-28 PA PA20088774001A patent/PA8774001A1/es unknown
- 2008-03-28 CL CL2008000899A patent/CL2008000899A1/es unknown
- 2008-03-28 TW TW097111568A patent/TW200843746A/zh unknown
- 2008-03-28 UY UY30987A patent/UY30987A1/es not_active Application Discontinuation
-
2009
- 2009-09-08 ZA ZA200906210A patent/ZA200906210B/xx unknown
- 2009-09-09 CR CR11019A patent/CR11019A/es unknown
- 2009-09-10 IL IL200862A patent/IL200862A0/en unknown
- 2009-09-24 TN TNP2009000388A patent/TN2009000388A1/fr unknown
- 2009-09-24 MA MA32230A patent/MA31260B1/fr unknown
- 2009-09-28 NI NI200900177A patent/NI200900177A/es unknown
- 2009-09-28 DO DO2009000229A patent/DOP2009000229A/es unknown
- 2009-09-28 GT GT200900256A patent/GT200900256A/es unknown
- 2009-09-29 EC EC2009009660A patent/ECSP099660A/es unknown
- 2009-10-28 SM SM200900085T patent/SMP200900085B/it unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP099660A (es) | 2009-10-30 |
CN101679382A (zh) | 2010-03-24 |
AU2008234954A1 (en) | 2008-10-09 |
PE20081897A1 (es) | 2009-02-09 |
CL2008000899A1 (es) | 2009-02-20 |
DOP2009000229A (es) | 2009-10-31 |
EA200901212A1 (ru) | 2010-04-30 |
PA8774001A1 (es) | 2008-11-19 |
GT200900256A (es) | 2010-03-15 |
UY30987A1 (es) | 2008-10-31 |
CR11019A (es) | 2009-10-20 |
NI200900177A (es) | 2010-09-09 |
KR20090122403A (ko) | 2009-11-27 |
IL200862A0 (en) | 2010-05-17 |
AU2008234954B9 (en) | 2012-02-02 |
JP2010522723A (ja) | 2010-07-08 |
AU2008234954B2 (en) | 2011-10-27 |
TN2009000388A1 (en) | 2010-12-31 |
TW200843746A (en) | 2008-11-16 |
BRPI0810082A2 (pt) | 2014-10-21 |
SMP200900085B (it) | 2010-11-12 |
AR065860A1 (es) | 2009-07-08 |
MX2009010413A (es) | 2009-10-20 |
SMAP200900085A (it) | 2010-01-19 |
WO2008119741A3 (fr) | 2008-12-04 |
US20100125064A1 (en) | 2010-05-20 |
WO2008119741A2 (fr) | 2008-10-09 |
CA2682483A1 (fr) | 2008-10-09 |
US8053457B2 (en) | 2011-11-08 |
ZA200906210B (en) | 2010-05-26 |
EP2142535A2 (fr) | 2010-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
ATE475650T1 (de) | Positive allosterische chinolon-m1- rezeptormodulatoren | |
MA31952B1 (fr) | Pyrrolopyrimidines et pyrrolopyridines | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
EP1841426A4 (fr) | Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu'inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d'alzheimer | |
ME00954B (fr) | Composés amino-hétérocycliques | |
ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
TN2009000551A1 (fr) | Nouveaux composes chimiques | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
ATE507204T1 (de) | Isoindolin-verbindungen und deren verwendungen | |
MA30084B1 (fr) | Triazolopyridazines en tant que modulateurs de la tyrosine kinase | |
MA33593B1 (fr) | Composés hétérocycliques et leurs utilisations | |
TNSN07070A1 (fr) | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases | |
MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
EA200800172A1 (ru) | 2,4-диаминопиримидины как ингибиторы aurora | |
MA33302B1 (fr) | 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale | |
MA30041B1 (fr) | Immunoglobulines | |
ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
BRPI0409622A (pt) | derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer | |
EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. |